Literature DB >> 9489964

Thyroid hormone and cardiovascular disease.

M Gomberg-Maitland1, W H Frishman.   

Abstract

Thyroid hormone directly affects the heart and peripheral vascular system. The hormone can increase myocardial inotropy and heart rate and dilate peripheral arteries to increase cardiac output. An excessive deficiency of thyroid hormone can cause cardiovascular disease and aggravate many preexisting conditions. In severe systemic illness and after major surgical procedures changes in thyroid function can occur, leading to the "euthyroid sick syndrome." Patients will have normal or decreased levels of T4, decreased free and total T3, and usually normal levels of thyroid stimulating hormone. This syndrome may be an adaptive response to systemic illness that usually will revert to normal without hormone supplementation as the illness subsides. Recently, however, many investigators have explored the benefits of thyroid hormone supplementation in those diseases associated with euthyroid sick syndrome. Thyroid hormone's effects on the cardiovascular system make it an attractive therapy for those patients with impaired hemodynamics and low T3. Thyroid hormone has also been considered a treatment for patients with congestive heart failure, for patients undergoing cardiopulmonary bypass and heart transplantation, and for patients with hyperlipidemia. At present there is no evidence suggesting a favorable treatment outcome using thyroid hormone supplementation for any systemic condition except in those patients with documented hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489964     DOI: 10.1016/s0002-8703(98)70081-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  23 in total

1.  Combined cardiothoracic surgery and interventions of the para/thyroid gland. A rare clinical cooperation.

Authors:  J Litmathe; M Kurt; U Boeken; A Roehrborn; P Feindt; E Gams
Journal:  Z Kardiol       Date:  2005-01

Review 2.  Thyroid and aging.

Authors:  Mouhammed Habra; Nicholas J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

3.  AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart failure and acute respiratory failure.

Authors:  S Savastano; V Cannavale; R Valentino; A P Tommaselli; R Rossi; A Luciano; L Tauchmanovà; A Mariano; L Mazzitelli; V Macchia; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 4.  Thyroid hormones and cardiac remodeling.

Authors:  Dennis V Cokkinos; Stavros Chryssanthopoulos
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

5.  Thyrotropin dysregulation during a non-thyroidal illness: transient hypothalamic hypothyroidism?

Authors:  U M Kabadi
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

6.  Investigation of tissue factor and other hemostatic profiles in experimental hypothyroidism.

Authors:  A Ata Alturfan; Ebru Emekli Alturfan; Nuran Dariyerli; Emel Zengin; Erman Aytac; Gunnur Yigit; Emine Kokoglu
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

7.  Changes in brain size with treatment in patients with hyper- or hypothyroidism.

Authors:  Angela Oatridge; Maria L Barnard; Basant K Puri; Simon D Taylor-Robinson; Joseph V Hajnal; Nadeem Saeed; Graeme M Bydder
Journal:  AJNR Am J Neuroradiol       Date:  2002-10       Impact factor: 3.825

8.  Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.

Authors:  R Chadarevian; C Jublanc; E Bruckert; P Giral; A Ankri; L Leenhardt; J Chapman; G Turpin
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

9.  Thyroid function is associated with presence and severity of coronary atherosclerosis.

Authors:  J Auer; R Berent; T Weber; E Lassnig; B Eber
Journal:  Clin Cardiol       Date:  2003-12       Impact factor: 2.882

Review 10.  Myocardial protection in man--from research concept to clinical practice.

Authors:  Dennis V Cokkinos; Costas Pantos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.